CoChat

Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST

Open access

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 13 of the 37 sources its claims cite were checked for support.

Abstract

PURPOSE: Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies in ROS1 + non–small cell lung cancer. METHODS: TRUST-I and TRUST-II were phase II, single-arm, open-label, nonrandomized, multicenter trials. Efficacy outcomes were pooled from TRUST-I and TRUST-II pivotal cohorts. The safety population comprised all patients treated with once-daily oral taletrectinib 600 mg pooled across the taletrectinib clinical program. The primary end point was independent review committee–assessed confirmed objective response rate (cORR). Secondary outcomes included intracranial (IC)-ORR, progression-free survival (PFS), duration of response (DOR), and safety. RESULTS: As of June 7, 2024, the efficacy-evaluable population included 273 patients in TRUST-I and TRUST-II. Among TKI-naïve patients (n = 160), the cORR was 88.8% and the IC-cORR was 76.5%; in TKI-pretreated patients (n = 113), the cORR was 55.8% and the IC-cORR was 65.6%. In TKI-naïve patients, the median DOR and median PFS were 44.2 and 45.6 months, respectively. In TKI-pretreated patients, the median DOR and median PFS were 16.6 and 9.7 months. The cORR in patients with G2032R mutation was 61.5% (8 of 13). Among 352 patients treated with taletrectinib 600 mg once daily, the most frequent treatment-emergent adverse events (TEAEs) were GI events (88%) and elevated AST (72%) and ALT (68%); most were grade 1. Neurologic TEAEs were infrequent (dizziness, 21%; dysgeusia, 15%) and mostly grade 1. TEAEs leading to discontinuations (6.5%) were low. CONCLUSION: Taletrectinib showed a high response rate with durable responses, robust IC activity, prolonged PFS, favorable safety, and low rates of neurologic adverse events in TKI-naïve and pretreated patients.

Overview

CoChat Summary

TL;DR

Taletrectinib showed high, durable responses and robust intracranial activity in ROS1+ non–small cell lung cancer in an integrated analysis of TRUST-I and TRUST-II. It had favorable safety with low rates of neurologic adverse events.

Key findings

  • In TKI-naïve patients (n = 160), the confirmed objective response rate (cORR) was 88.8%, intracranial cORR (IC-cORR) was 76.5%, median duration of response (DOR) was 44.2 months, and median progression-free survival (PFS) was 45.6 months.
  • In TKI-pretreated patients (n = 113), cORR was 55.8%, IC-cORR was 65.6%, median DOR was 16.6 months, and median PFS was 9.7 months.
  • Among patients with G2032R mutation, cORR was 61.5% (8 of 13).
  • In the safety population (n = 352), common treatment-emergent adverse events were GI events (88%), elevated AST (72%), and elevated ALT (68%); neurologic events included dizziness (21%) and dysgeusia (15%), mostly grade 1; TEAEs leading to discontinuation were 6.5%.

Methods

  • TRUST-I and TRUST-II were phase II, single-arm, open-label, nonrandomized, multicenter trials; efficacy was pooled from pivotal cohorts, and safety included all patients treated with once-daily oral taletrectinib 600 mg across the clinical program.
  • The primary end point was independent review committee–assessed confirmed objective response rate; secondary outcomes included IC-ORR, PFS, DOR, and safety. As of June 7, 2024, the efficacy-evaluable population included 273 patients; safety population included 352 patients.
  • Analyses used Clopper-Pearson 95% CIs, Kaplan-Meier estimates for PFS and DOR, and Greenwood/Brookmeyer-Crowley methods for corresponding CIs.

Limitations

  • Stated: limited number of TKI-pretreated patients with baseline mutation status (71.7% unavailable) and follow-up biopsies because of difficulty obtaining rebiopsies at progression, limiting translational data on resistance mutations.
  • Stated: cross-trial comparisons should be interpreted cautiously.
  • Evident: the trials were single-arm, open-label, and nonrandomized without a concurrent control; the safety population was pooled across multiple studies, including a phase II trial in NTRK+ tumors and a phase I trial in Japan.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1200/jco-25-00275

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG 1. Analysis populations. Data cutoff: June 7, 2024. Patient flowcharts in the (A) efficacy and (B) safety populations. aREP included patients with ROS1+ NSCLC with ≥one measurable baseline lesion per RECIST v1.1 by IRC receiving ≥one dose of taletrectinib. One patient from TRUST-I was excluded from the REP because of a secondary malignancy. bThe integrated safety population described reflects exposure to taletrectinib as a single agent dosed at 600 mg orally once daily until disease progression or unacceptable toxicity in 352 patients with ROS1+ NSCLC (N = 337) and other solid tumors (n = 15). IRC, independent review committee; NSCLC, non–small cell lung cancer; REP, response-evaluable population; TKI, tyrosine kinase inhibitor.
FIG 1. Analysis populations. Data cutoff: June 7, 2024. Patient flowcharts in the (A) efficacy and (B) safety populations. aREP included patients with ROS1+ NSCLC with ≥one measurable baseline lesion per RECIST v1.1 by IRC receiving ≥one dose of taletrectinib. One patient from TRUST-I was excluded from the REP because of a secondary malignancy. bThe integrated safety population described reflects exposure to taletrectinib as a single agent dosed at 600 mg orally once daily until disease progression or unacceptable toxicity in 352 patients with ROS1+ NSCLC (N = 337) and other solid tumors (n = 15). IRC, independent review committee; NSCLC, non–small cell lung cancer; REP, response-evaluable population; TKI, tyrosine kinase inhibitor.CC BY-NC-ND · PubMed Central
FIG 2. IRC-assessed BOR of taletrectinib in TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC. Overall best percent change in the sum of diameters of target lesions from baseline in (A) TKI-naïve (n = 160; three patients with confirmed BOR as not evaluable are not displayed in the waterfall plot) and (B) TKI-pretreated (n = 113; six patients with confirmed BOR as not evaluable are not displayed in the waterfall plot) patients and IC best percent change in the sum of diameters of IC measurable lesions from baseline in (C) TKI-naïve (n = 17; one patient confirmed with BOR as not evaluable is not displayed in the waterfall plot) and (D) TKI-pretreated (n = 32; one patient confirmed with BOR as not evaluable is not displayed in the waterfall plot) patients. aOne patient had a best percent change of 0 and BOR as SD. BOR, best overall response; CR, complete response; IC, intracranial; IRC, independent review committee; NSCLC, non–small cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.
FIG 2. IRC-assessed BOR of taletrectinib in TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC. Overall best percent change in the sum of diameters of target lesions from baseline in (A) TKI-naïve (n = 160; three patients with confirmed BOR as not evaluable are not displayed in the waterfall plot) and (B) TKI-pretreated (n = 113; six patients with confirmed BOR as not evaluable are not displayed in the waterfall plot) patients and IC best percent change in the sum of diameters of IC measurable lesions from baseline in (C) TKI-naïve (n = 17; one patient confirmed with BOR as not evaluable is not displayed in the waterfall plot) and (D) TKI-pretreated (n = 32; one patient confirmed with BOR as not evaluable is not displayed in the waterfall plot) patients. aOne patient had a best percent change of 0 and BOR as SD. BOR, best overall response; CR, complete response; IC, intracranial; IRC, independent review committee; NSCLC, non–small cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.CC BY-NC-ND · PubMed Central
FIG 3. DOR and PFS by IRC assessment of taletrectinib in TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC. (A) DOR in TKI-naïve patients, (B) PFS in TKI-naïve patients, (C) DOR in TKI-pretreated patients, and (D) PFS in TKI-pretreated patients. DOR, duration of response; IRC, independent review committee; NSCLC, non–small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
FIG 3. DOR and PFS by IRC assessment of taletrectinib in TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC. (A) DOR in TKI-naïve patients, (B) PFS in TKI-naïve patients, (C) DOR in TKI-pretreated patients, and (D) PFS in TKI-pretreated patients. DOR, duration of response; IRC, independent review committee; NSCLC, non–small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.CC BY-NC-ND · PubMed Central
FIG A1. Study designs of (A) TRUST-I (ClinicalTrials.gov identifier: NCT04395677) and (B) TRUST-II (ClinicalTrials.gov identifier: NCT04919811). aA dose-confirmation lead-in stage evaluated the safety of taletrectinib 400 mg once daily (n = 3) and 600 mg once daily (n = 3). bSafety was analyzed in patients receiving ≥one dose of taletrectinib until 30 days after the last dose of taletrectinib or the start date of new anticancer therapy minus 1 day, whichever occurred first. cOr ≥20 years, as required by local regulations. dOne previous ROS1 TKI (crizotinib or entrectinib). BOR, best overall response; cORR, confirmed ORR; CT, chemotherapy; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, intracranial; IRC, independent review committee; mRECIST, modified RECIST; NSCLC, non–small cell lung cancer; ORR, objective response rate; PFS, progression-free survival; TTR, time to response; TKI, tyrosine kinase inhibitor.
FIG A1. Study designs of (A) TRUST-I (ClinicalTrials.gov identifier: NCT04395677) and (B) TRUST-II (ClinicalTrials.gov identifier: NCT04919811). aA dose-confirmation lead-in stage evaluated the safety of taletrectinib 400 mg once daily (n = 3) and 600 mg once daily (n = 3). bSafety was analyzed in patients receiving ≥one dose of taletrectinib until 30 days after the last dose of taletrectinib or the start date of new anticancer therapy minus 1 day, whichever occurred first. cOr ≥20 years, as required by local regulations. dOne previous ROS1 TKI (crizotinib or entrectinib). BOR, best overall response; cORR, confirmed ORR; CT, chemotherapy; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, intracranial; IRC, independent review committee; mRECIST, modified RECIST; NSCLC, non–small cell lung cancer; ORR, objective response rate; PFS, progression-free survival; TTR, time to response; TKI, tyrosine kinase inhibitor.CC BY-NC-ND · PubMed Central
FIG A2. Change in size of target lesions relative to baseline over time in (A) TKI-naïve and (B) TKI-pretreated patients. Reduction in target lesion size over time in (A) TKI-naïve patients (three patients had confirmed BOR as not evaluable and are not displayed) and (B) TKI-pretreated patients (the target lesion sum of diameters from baseline of one patient had increased 136.5%, which was cut at 100% in the figure because of page size limit; six patients had confirmed BOR as not evaluable and are not displayed in the spider plot). BOR, best overall response; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.
FIG A2. Change in size of target lesions relative to baseline over time in (A) TKI-naïve and (B) TKI-pretreated patients. Reduction in target lesion size over time in (A) TKI-naïve patients (three patients had confirmed BOR as not evaluable and are not displayed) and (B) TKI-pretreated patients (the target lesion sum of diameters from baseline of one patient had increased 136.5%, which was cut at 100% in the figure because of page size limit; six patients had confirmed BOR as not evaluable and are not displayed in the spider plot). BOR, best overall response; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.CC BY-NC-ND · PubMed Central
FIG A3. Responses per IRC by subgroup in the response-evaluable population in (A) TKI-naïve and (B) TKI-pretreated patients. ORR in (A) TKI-naïve patients and (B) TKI-pretreated patients. ECOG, Eastern Cooperative Oncology Group; IRC, independent review committee; mRECIST, modified RECIST; ORR, objective response rate; TKI, tyrosine kinase inhibitor.
FIG A3. Responses per IRC by subgroup in the response-evaluable population in (A) TKI-naïve and (B) TKI-pretreated patients. ORR in (A) TKI-naïve patients and (B) TKI-pretreated patients. ECOG, Eastern Cooperative Oncology Group; IRC, independent review committee; mRECIST, modified RECIST; ORR, objective response rate; TKI, tyrosine kinase inhibitor.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

8 Valid · 2 Not valid · 9 Not checked · 47 Own results and interpretations

33 more claims

Create a free account to see all 66 claims and to verify the 24 references still open.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 17
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. US Food and Drug Administration: Guidance for Industry—Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Silver Spring, MD, U.S. Department of Health and Human Services, 2009

Cited by

See all 63

Metadata

Authors
Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., Fan, H., Wang, X., Li, S., Lai, R. K., Ran, F., Zhang, X., Chen, W., Bazhenova, L., & Zhou, C.
Affiliations
  • Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France
  • Tongji University (CN)
  • Cleveland Clinic (US)
  • University of Toronto (CA)
  • National Cancer Center Hospital (JP)
  • University of Milan, Milan, Italy
  • University of California, Irvine (US)
  • Vall d'Hebron Hospital Universitari (ES)
  • Central South University (CN)
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Guangdong Pharmaceutical University (CN)
  • Nuvation Bio, New York, NY
  • Moores Cancer Center (US)
Corresponding author
Zhou, Caicun
Venue
Journal of Clinical Oncology
Published
2025-06
Volume
43
Issue
16
Pages
1920-1929
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4409129984
Cited by
63
References
25
Citations by year
2026: 43 · 2025: 20
FWCI
41.42
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
taletrectinib, ROS1-positive non-small cell lung cancer, tyrosine kinase inhibitors, objective response rate, intracranial response, progression-free survival, duration of response, treatment-emergent adverse events, neurological adverse events
MeSH terms
Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anilides, Carcinoma, Non-Small-Cell Lung, Female, Humans, Imidazoles, Lung Neoplasms, Male, Middle Aged, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Pyrazoles, Pyridazines, Quinolines, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST. https://app.cochat.ai/papers/10.1200/jco-25-00275
The paper
Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., Fan, H., Wang, X., Li, S., Lai, R. K., Ran, F., Zhang, X., Chen, W., Bazhenova, L., & Zhou, C. (2025). Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00275

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.